FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

dated January 15, 2009

 

Commission File Number 0-51373

 

CHEMGENEX PHARMACEUTICALS LIMITED

(Exact Name as Specified in its Charter)

 

N/A

(Translation of Registrant’s Name)

 

Level 4,199 Moorabool Street

Geelong 3220, Victoria

Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x        Form 40-F   o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  o       No  x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  Not applicable.

 

 

 



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Date: January 15, 2009

 

 

CHEMGENEX PHARMACEUTICALS
LIMITED

 

 

 

 

 

By:

/s/ Greg R. Collier

 

 

Name:

Greg R. Collier

 

 

Title:

Managing Director

 

2



 

EXHIBIT INDEX

 

Exhibit

 

Description

 

 

 

99.1

 

Release, January 14, 2009

 

 

 

99.2

 

Corporate presentation January 2009

 

3


Chemgenex (NASDAQ:CXSP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Chemgenex 차트를 더 보려면 여기를 클릭.
Chemgenex (NASDAQ:CXSP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Chemgenex 차트를 더 보려면 여기를 클릭.